We are global leaders in delivering treatments for people with hemophilia and other bleeding disorders.
At Shire, we’re focused on serving people with rare diseases and other highly specialized conditions. These diseases are often misunderstood, undiagnosed, and life threatening.
As we look to the future, we will continue to address some of the greatest challenges associated with hematologic disorders. To this end, we have joined with Baxalta, formerly Baxter, which has a rich history of bringing treatments to the bleeding disorders community based on a deep understanding of the patient journey. The company introduced a number of treatment firsts for patients with bleeding disorders, including the development of the first recombinant factor VIII treatment, the first needleless transfer device, the first recombinant factor VIII treatment free of blood-based additives, and the first and only recombinant treatment for von Willebrand disease in adults.1
With over 22,000 employees across more than 100 countries, Shire’s expanded global reach and best-in-class products offer the potential to help even more patients around the world with significant unmet needs.
To learn more, visit www.shire.com today.
- Data on file. Westlake Village, CA; Baxter Healthcare Corporation.